Vaccine Advisers Recommend New RSV Vaccine for Infants

A group of outside advisers to the Centers for Disease Control and Prevention (CDC) voted 5-2 to recommend the use of Merck’s new antibody vaccine, Enflonsia (clesrovimab), that can protect babies from respiratory syncytial virus (RSV).

Flebogamma (IVIG) Effective in Treating Post-Polio Syndrome

Grifols announced positive results from its Phase II/III clinical trial evaluating the efficacy and safety of Flebogamma 5% DIF (intravenous immune globulin [IVIG]) to treat patients with post-polio syndrome, which demonstrated a significant improvement in distance walked compared to placebo.  

FDA Approves Immune Checkpoint Inhibitor for Head and Neck Cancer

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) to treat patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (combined positive score [CPS] ≥1) as determined by an FDA-approved test.

IVIG Effectively Increased Platelet Counts in Maternal Thrombocytopenia

A recent study that sought to evaluate the efficacy of intravenous immune globulin (IVIG) and identify predictors of platelet response in pregnant persons with moderate-to-severe thrombocytopenia, as well as to optimize clinical decisions and resource use, has found that IVIG effectively increases platelet counts. 

Nasal Spray Blocks Infuenza in Mice

Scientists at Ohio State University have created an antibody that was successful in protecting a majority of the tested mice from lethal influenza (flu) doses, even preventing some from experiencing any symptoms at all.

New Antibiotic Enters Phase III Trials to Fight Superburg

Roche’s novel antibiotic zosurabalpin is  entering Phase III testing to determine its effectiveness in protecting against carbapenem-resistant Acinetobacter baumannii (CRAB), am antimicrobial resistance (AMR) drug, or “superbug,” that is considered an “urgent threat” by the Centers for Disease Control and Prevention (CDC).

FDA Approves Alzheimer’s Blood Test

The U.S. Food and Drug Administration has given marketing clearance to the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, a blood test to help diagnose Alzheimer’s disease for adults 55 and older who are showing signs and symptoms of the disease. It is the first test to be approved to aid in the early detection of the disease in the United States.